Medical News

RSS

Common fungus might serve as therapeutic agent for plant and human health

Researchers have come closer to understanding how a common fungus "makes its living in the soil," which could lead to its possible "career change" as a therapeutic agent for plant and human health.

2 Mar 2011

Calypte Biomedical completes new Aware HIV-1/2 oral fluid rapid test internal studies

Calypte Biomedical Corporation, a developer, manufacturer and marketer of HIV diagnostic tests, today announced successful completion of internal studies of its new Aware HIV-1/2 oral fluid rapid test for the US and international markets.

2 Mar 2011

FDA clears Meridian's illumigene C. difficile molecular amplification test

Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it has received clearance from the U.S. Food and Drug Administration for a new pediatric claim for its illumigene C. difficile molecular amplification test. C. difficile is a bacterium that is frequently associated with antibiotic therapy often causing diarrhea and, in severe cases, a life-threatening inflammation of the colon.

2 Mar 2011

International Surf Resorts to acquire BioZone Laboratories

International Surf Resorts, Inc., to be renamed BioZone Pharmaceuticals, Inc., today announced a binding option and letter of intent with BioZone Laboratories, Inc. and related companies.

2 Mar 2011

BigThink.com launches breakthroughs: Discussion highlighting cutting-edge cancer research

Everyone knows someone that has been touched by cancer. Over one and a half million Americans will be diagnosed with some form of cancer in 2011, and more than 560,000 will die from the disease, accounting for 1 out of every 5 deaths.

2 Mar 2011

Researchers find mineral deficiency increases type 2 diabetes risk in African-Americans

Lower potassium levels in the blood may help explain why African-Americans are twice as likely to be diagnosed with type 2 diabetes as whites, according to a new study by Johns Hopkins researchers.

2 Mar 2011

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

German researchers have found a significant association of IL28B genotypes to interferon-based antiviral treatment outcome, and to graft inflammation caused by hepatitis C virus (HCV). The study determined that the presence of G-allele serves as a marker for severe HCV-induced graft inflammation, as well as a predictor for unsuccessful treatment. Study findings—the largest to report on the role IL28B variants in a transplant cohort with recurrent HCV—are published in the March issue of Liver Transplantation, a journal of the American Association for the Study of Liver Diseases.

2 Mar 2011

Oxygen Biotherapeutics receives U.S. Army grant for studies of Oxycyte

Oxygen Biotherapeutics, Inc. (NASDAQ and SIX Swiss Exchange: OXBT) today announced it has received a $2,075 million two-year grant from the U.S. Army to study the Company’s proprietary Oxycyte® PFC emulsion as a therapeutic intervention focused on reducing brain damage in victims of traumatic brain injury (TBI).

2 Mar 2011

Health care needs to look to aviation industry to improve safety

In a commentary published today in the Journal of the American Medical Association, a leading patient safety expert argues that failure to integrate new electronic equipment in modern hospital operating rooms and intensive care units results in diagnostic mistakes, failures to identify deteriorating patients, communication errors and inefficient work.

2 Mar 2011

Viruses that are natural part of human genome may retrovirus culprit

A retrovirus that inserted itself into the human genome thousands of years ago may be responsible for some cases of the neurodegenerative disease amyotrophic lateral sclerosis (ALS), also known as Lou Gherig’s disease. The finding, made by Johns Hopkins scientists, may eventually give researchers a new way to attack this universally fatal condition.

2 Mar 2011

Cyberonics third quarter net sales increase 15.3% to $47.1 million

Cyberonics, Inc., a global leader in epilepsy management, today announced results for the quarter ended January 28, 2011.

2 Mar 2011

PreTreat Complete is now available for public to reduce migraine headaches

A new migraine supplement, PreTreat Complete, with active compounds designed to reduce the frequency and intensity of migraine headaches is now available.

2 Mar 2011

Reliv fourth-quarter net sales decrease to $18.5 million

Reliv International, Inc. a maker of nutritional supplements that promote optimal health, today reported its financial results for the fourth-quarter and full-year of 2010.

2 Mar 2011

Novabay commences NVC-422 catheter Phase 2 trial to treat UCBE

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing its first-in-class, anti-infective Aganocide compounds for the local non-systemic treatment and prevention of antibiotic-resistant infections, today provided an update on its Phase 2 clinical trial for the use of its lead compound, NVC-422, to prevent urinary catheter blockage and encrustation which is often a contributing factor to urinary tract infections in chronically catheterized patients.

2 Mar 2011

Achillion fourth quarter revenue is $2 million for three months ended December 31, 2010

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three and twelve months ended December 31, 2010.

2 Mar 2011

Cellastim and Optiferrin enable development of xeno-free and blood product-free expansion media

A recent study demonstrated that Cellastim and Optiferrin deliver superior xeno-free and animal-free solutions for primary cell and stem cell expansion media.

2 Mar 2011

Research: Blocking two cell DNA repair routes at once can provide new way to treat bowel cancer

Cancer Research UK-funded scientists have discovered that blocking two cell DNA repair routes at once could provide a completely new way to treat bowel cancer and potentially other cancers, according to research published in Cancer Research, today.

2 Mar 2011

SCAI statement highlights multiple recommendations for evaluating PCI quality at cardiac facilities

Today the Society for Cardiovascular Angiography and Interventions announced the publication of recommendations for assessing and improving program quality at percutaneous coronary intervention programs at cardiac facilities.

2 Mar 2011

Level 3, ALA sign agreement to provide DIA, voice services to improve lung health awareness

Level 3 Communications, Inc. today announced that it has signed an agreement with the American Lung Association of the Midland States, a non-profit healthcare organization serving Kentucky, Michigan, Ohio and Tennessee, to provide dedicated Internet access and voice services in support of its mission to improve lung health awareness.

2 Mar 2011

Virostatics' VS411 Phase 2a trial results against HIV presented at 18th CROI

An analysis of immune markers measured in a sub-study of ViroStatics' proof-of-concept Phase 2a trial showed that VS411 was able to reduce immune activation while producing a median 1.5 log10 reduction in viral load.

2 Mar 2011

Medical News

Common fungus might serve as therapeutic agent for plant and human health

Calypte Biomedical completes new Aware HIV-1/2 oral fluid rapid test internal studies

FDA clears Meridian's illumigene C. difficile molecular amplification test

International Surf Resorts to acquire BioZone Laboratories

BigThink.com launches breakthroughs: Discussion highlighting cutting-edge cancer research

Researchers find mineral deficiency increases type 2 diabetes risk in African-Americans

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

Oxygen Biotherapeutics receives U.S. Army grant for studies of Oxycyte

Health care needs to look to aviation industry to improve safety

Viruses that are natural part of human genome may retrovirus culprit

Cyberonics third quarter net sales increase 15.3% to $47.1 million

PreTreat Complete is now available for public to reduce migraine headaches

Reliv fourth-quarter net sales decrease to $18.5 million

Novabay commences NVC-422 catheter Phase 2 trial to treat UCBE

Achillion fourth quarter revenue is $2 million for three months ended December 31, 2010

Cellastim and Optiferrin enable development of xeno-free and blood product-free expansion media

Research: Blocking two cell DNA repair routes at once can provide new way to treat bowel cancer

SCAI statement highlights multiple recommendations for evaluating PCI quality at cardiac facilities

Level 3, ALA sign agreement to provide DIA, voice services to improve lung health awareness

Virostatics' VS411 Phase 2a trial results against HIV presented at 18th CROI

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Latest News